RecruitingNCT06778746

Use of Biologics for Severe Asthma in Hong Kong


Sponsor

Chinese University of Hong Kong

Enrollment

360 participants

Start Date

Dec 26, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The landscape of biologics therapy used in Hong Kong is currently unknown. The purpose of this study is to conduct a retrospective analysis of the use of biologics treatment for severe asthma in Hong Kong. The study aims to assess the landscape of biologics usage, evaluate the characteristics and conditions of patients before and after receiving biologic therapy, and provide insights into the effectiveness and safety of these treatments in the local population.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Patients aged 18 years or older.
  • Patients diagnosed with severe asthma per the Global Initiative for Asthma (GINA) guidelines.
  • Patients who have received biologic therapy for treatment of asthma (including those who received just one dose to allow assessment of the reason for withdrawal)

Exclusion Criteria1

  • \- Patients with respiratory diseases with other known significant respiratory diseases, including tuberculosis (TB)-destroyed lung parenchyma, history of lung resection and lung cancer

Interventions

OTHERno interventions

No interventions, this is an observational study


Locations(1)

Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, NT, HK

Hong Kong, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06778746


Related Trials